Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. MoonLake Immunotherapeutics is the next stock on our list.

TheFly reported on January 14 that Goldman Sachs downgraded MLTX to Sell from Neutral and set a price target of $10, up from $8. The firm noted that sonelokimab’s advancement into Phase 3 for palmoplantar pustulosis provides an additional opportunity, but it continues to view significant approvability risk in hidradenitis suppurativa. Given VELA-2’s failure to meet its primary endpoint, Goldman Sachs does not believe the FDA’s procedural guidance meaningfully reduces approval uncertainty.

Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play

Separately, earlier this month, on January 9, H.C. Wainwright raised the price target on MoonLake Immunotherapeutics (NASDAQ:MLTX) to $32 from $26 and maintained a Buy rating. The firm noted that the outcome of the FDA Type B meeting provides a defined path toward regulatory registration.

MoonLake Immunotherapeutics (NASDAQ:MLTX) is a clinical‑stage biopharmaceutical company that develops revolutionary Nanobody therapies to treat inflammatory skin and joint diseases. Its primary asset, sonelokimab, targets IL‑17A and IL‑17F to reduce inflammation in disorders like hidradenitis suppurativa and psoriatic arthritis.

While we acknowledge the risk and potential of MLTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MLTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.